Pathology Department, Kecioren Training and Research Hospital, University of Health Sciences.
Pathology Department.
Appl Immunohistochem Mol Morphol. 2020 Aug;28(7):532-537. doi: 10.1097/PAI.0000000000000791.
"Special AT-rich sequence-binding protein-1" (SATB1) is a global genome organizer and is found to have effects on carcinogenesis and progression of various malignancies including colorectal carcinoma (CRC). We aimed to investigate the expression of SATB1 in CRC and colorectal adenomatous polyps (CAP), the correlation between clinicopathologic parameters, and overall survival. We examined 227 CRCs and 129 CAPs. SATB1 protein expression was evaluated by immunohistochemistry. We found higher SATB1 expression in adenomatous epithelium than in CRC tissues (55.0% vs. 42.7%, respectively) (P<0.05). None of the adjacent normal colorectal mucosa stained positive in CRC cases, and only one of the adjacent normal mucosa of the CAP cases was positive. SATB1 expression of left-sided CRC was higher than that of right-sided CRC (46.3% vs. 28.6%, respectively) (P<0.05), and SATB1 expression of conventional adenocarcinomas was higher than that of mucinous carcinomas (45.5% vs. 6.3%, respectively) (P<0.05). SATB1 expression was higher in CAPs consisting of high-grade dysplasia than in polyps with low-grade dysplasia (77.8% vs. 51.4%) (P<0.05). SATB1 expression did not correlate with patients' overall survival. In conclusion, due to the higher expression of SATB1 in CAP than in CRC, we think SATB1 may have a role in the early stages of carcinogenesis of CRCs. This is the first study investigating SATB1 expression in CAPs. Besides this is the first report that shows different SATB1 expressions in conventional colorectal adenocarcinoma and mucinous carcinoma, and also in right-sided and left-sided CRC. Our results, with supporting new studies, can provide SATB1 as a possible candidate for targeted therapy for CRC patients.
"特殊富含 AT 序列结合蛋白-1"(SATB1)是一种全基因组组织者,被发现对包括结直肠癌(CRC)在内的各种恶性肿瘤的发生和进展有影响。我们旨在研究 SATB1 在 CRC 和结直肠腺瘤性息肉(CAP)中的表达,以及与临床病理参数和总生存的相关性。我们检查了 227 例 CRC 和 129 例 CAP。通过免疫组织化学评估 SATB1 蛋白表达。我们发现腺瘤性上皮中的 SATB1 表达高于 CRC 组织(分别为 55.0%和 42.7%)(P<0.05)。CRC 病例的相邻正常结直肠黏膜无一例呈阳性,而 CAP 病例的仅有一例呈阳性。左侧 CRC 的 SATB1 表达高于右侧 CRC(分别为 46.3%和 28.6%)(P<0.05),传统腺癌的 SATB1 表达高于黏液癌(分别为 45.5%和 6.3%)(P<0.05)。由高级别异型增生组成的 CAP 的 SATB1 表达高于由低级别异型增生组成的息肉(分别为 77.8%和 51.4%)(P<0.05)。SATB1 表达与患者的总生存无关。总之,由于 SATB1 在 CAP 中的表达高于 CRC,我们认为 SATB1 可能在 CRC 发生的早期阶段起作用。这是第一项研究 SATB1 在 CAP 中的表达的研究。此外,这是第一项表明常规结直肠腺癌和黏液癌以及右侧和左侧 CRC 中 SATB1 表达不同的报告。我们的结果,结合新的研究,可以为 CRC 患者的靶向治疗提供 SATB1 作为可能的候选物。